Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on May 25, 2021. The report addresses a significant change in executive leadership regarding the Chief Financial Officer role.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation of CFO: Thomas J. Russo, CFA, resigned as Chief Financial Officer, principal financial officer, and principal accounting officer, effective June 4, 2021, to pursue another opportunity.
- Interim Appointment: Michael P. Samar, Senior Vice President of Finance and Business Operations, will assume the functions of principal financial officer and principal accounting officer effective June 4, 2021.
- Compensation: No additional compensation will be provided to Mr. Samar for assuming these interim roles.
Outlook, Risks, and Management Commentary
The Company is currently evaluating next steps regarding the permanent chief financial officer role. The filing confirms there are no undisclosed arrangements or understandings regarding Mr. Samar's selection, nor are there any family relationships between Mr. Samar and other directors or officers requiring disclosure.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (June 4, 2021).
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Review Mr. Samar's tenure and background (joined Company in 2017; previously at Acorda Therapeutics and Biotie Therapies).
- Verify that no additional compensation was triggered by the interim appointment.